Company Profile

FerroKin BioSciences Inc
Profile last edited on: 7/16/2023      CAGE: 5BXM4      UEI: YNKEJVLDM3V8

Business Identifier: Iron chelator for iron-overload treatment
Year Founded
First Award
Latest Award
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

2729 Debbie Court
San Carlos, CA 94070
   (650) 218-5710
Location: Single
Congr. District: 15
County: San Mateo

Public Profile

Ferrokin Biosciences Inc. offers iron chelator for the treatment of iron-overload in patients with transfusion-dependent hereditary and acquired refractory anemias. The firm is a clinical stage biotechnology company dedicated to improving the management of patients with iron overload. They are currently developing a new treatment for transfusional iron overload. Iron overload is caused by chronic transfusion therapy. Patients with inherited anemias such as thalassemia and sickle cell disease require regular transfusions to maintain their health and sense of well-being. Patients with acquired anemias such as myelodysplastic syndrome develop transfusion-dependent anemia later in life. All patients receiving chronic transfusion therapy accumulate iron and may eventually require treatment for iron overload. The firm's lead medicine, FBS0701, is being evaluated in a comprehensive development program as a once-daily treatment in capsule form for patients with transfusional iron overload. In March 2012, irt was announced that Shire PLC had agreed to acquire FerroKin BioSciences Inc.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2010 1 NIH $100,000
Project Title: Enhanced Iron Removal With Peptide Linked Chelators Targeted To Ferritin

Key People / Management

  Hugh Young Rienhoff Jr -- President